Rift Valley Fever Clinical Trial
Official title:
A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift Valley Fever Virus
This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine
This study is being conducted to collect safety and immunogenicity data for the RVF vaccine, TSI-GSD 200, Lot 7, Run 2. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently). Subjects who respond with a titer of >1:40 may participate for study duration. Rift Valley Fever Vaccine, Inactivated, Dried (TSI GSD 200) will be administered in 1.0-mL doses SQ in the upper outer aspect of the arm. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00869713 -
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
|
Phase 2 | |
| Recruiting |
NCT05139524 -
RVF and Other Emerging Infectious Diseases in East and Central Africa
|
||
| Completed |
NCT04672824 -
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00287014 -
Rift Valley Fever in Kenya
|
N/A | |
| Completed |
NCT00584194 -
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
|
Phase 2 | |
| Completed |
NCT04754776 -
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
|
Early Phase 1 | |
| Completed |
NCT00415051 -
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
|
Phase 2 |